RHÖN-KLINIKUM Aktiengesellschaft
ISIN: DE0007042301
WKN: 704230
28 March 2024 09:00AM

EQS-News: RHÖN-KLINIKUM AG looks back on successful financial year 2023

RHÖN-KLINIKUM Aktiengesellschaft · ISIN: DE0007042301 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1869377

EQS-News: RHÖN-KLINIKUM Aktiengesellschaft / Key word(s): Annual Results/Annual Results
RHÖN-KLINIKUM AG looks back on successful financial year 2023

28.03.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

Corporate News

Bad Neustadt a. d. Saale | 28 March 2024

 

RHÖN-KLINIKUM AG looks back on successful financial year 2023


RHÖN-KLINIKUM AG has met its financial targets as per forecast. Revenues increased by 17.9 million euros to 1,464.0 million euros (previous year: 1,446.1 million euros), despite the discontinuation of reimbursements from the legislator under COVID-19 legislation. Consolidated profit improved by 13.3 million euros to 40.2 million euros (previous year: 26.9 million euros). Earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at 105.9 million euros (previous year: 105.6 million euros). A total of 881,775 patients (previous year: 855,333) were treated on an inpatient and outpatient basis in the Group’s hospitals and medical care centres – an increase of 3.1 per cent.

“In the past year as well, RHÖN-KLINIKUM AG demonstrated its financial efficiency and put in a solid performance. This is extremely positive given the highly fraught economic situation of hospitals in Germany. It confirms that we’re on the right path with our strategic orientation. We are especially grateful to our employees for their extraordinary commitment and to our patients for the trust they put in our medical, therapeutic and care expertise”, said Prof. Dr Tobias Kaltenbach, chairman of the Board of Management of RHÖN-KLINIKUM.


Acting strategically and sustainably

RHÖN-KLINIKUM AG continues to steadfastly pursue its strategic goals. The hospitals will focus on their core activities, i.e. on inpatient treatment services, with the goal of being able to provide patients with cutting-edge medical care at all sites. Moreover, the Company is investing in the expansion of outpatient care so that it can offer patients alternatives to an inpatient hospital stay meeting a high quality of medical care without having to sacrifice the standards of a treatment at a hospital. The focus is also on efforts to further expand digitalisation and to optimise clinical and administrative processes.

The healthcare group embraces its ecological obligations in addition to its medical, social and corporate responsibilities. RHÖN-KLINIKUM AG is looking to achieve CO2-greenhouse gas neutrality in Scope 1 and Scope 2 emissions by financial year 2040. To achieve that, the Company is investing in sustainable technologies and continuously optimising its processes at all sites to protect the environment.

“We see the most significant challenge of supplying sustainable energy to our hospital sites. That is why we have been closely scrutinising both consumption and efficiency and have come up with a transformation concept showing energy conservation and utilisation potential. The measures derived from this are the roadmap for our environmental strategy”, Kaltenbach explained.


Outlook for 2024

For the coming financial year we expect revenues of 1.6 billion euros within a range of +/- 5 per cent.
For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between 110 million euros and 120 million euros.

This forecast reflects the further heightened regulatory interference by the German legislator.

We point out that our outlook is further subject to considerable uncertainties in connection with the numerous global crises in the form of inflation and price increases and any regulatory measures impacting our remuneration structure in 2024.

 

RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. The hospitals offer excellent medical care with a direct tie-in to universities and research facilities. Each year some 882,000 patients are treated at our five sites of Campus Bad Neustadt, Klinikum Frankfurt (Oder), Universitätsklinikum Gießen and Universitätsklinikum Marburg (UKGM) as well as Zentralklinik Bad Berka. The Company employs over 18,200 persons. The innovative RHÖN Campus approach for cross-sector and future-oriented healthcare delivery in rural areas, the steadfast continuation of the gradual digital transformation within the Company as well as the strategic partnership with Asklepios are important elements of our corporate strategy. RHÖN-KLINIKUM AG is an independent Company operating under the umbrella of Asklepios Kliniken GmbH & Co. KGaA.   www.rhoen-klinikum-ag.com


Annual Report 2023
https://en.rhoen-klinikum-ag.com/annualreport


Contact:
RHÖN-KLINIKUM AG | Head of Corporate Finance, Treasury, Investor Relations & Sustainability
Julian Schmitt 
T. +49 9771 65-12250 | julian.schmitt@rhoen-klinikum-ag.com


RHÖN-KLINIKUM AG | Schlossplatz 1 | D-97616 Bad Neustadt a. d. Saale



28.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: RHÖN-KLINIKUM Aktiengesellschaft
Salzburger Leite 1
97616 Bad Neustadt a.d.Saale
Germany
Phone: +49 (0)9771 - 65-0
Fax: +49 (0)9771 - 97 467
E-mail: rka@rhoen-klinikum-ag.com
Internet: www.rhoen-klinikum-ag.com
ISIN: DE0007042301
WKN: 704230
Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID: 1869377

 
End of News EQS News Service

1869377  28.03.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1869377&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 1.232,91 1.303,90 1.360,16 1.402,01 1.446,09 1.463,98 1.620,00
EBITDA1,2 125,54 125,33 80,23 101,16 105,65 105,88 117,00
EBITDA-Margin3 10,18 9,61 5,90 7,22 7,31 7,23 7,22
EBIT1,4 64,94 56,80 10,60 30,52 36,11 40,40 53,00
EBIT-Margin5 5,27 4,36 0,78 2,18 2,50 2,76 3,27
Net Profit (Loss)1 51,19 44,48 2,46 30,23 26,94 40,17 34,00
Net-Margin6 4,15 3,41 0,18 2,16 1,86 2,74 2,10
Cashflow1,7 49,50 47,30 113,30 97,50 41,30 109,00 85,00
Earnings per share8 0,73 0,65 0,02 0,42 0,38 0,58 0,51
Dividend per share8 0,29 0,00 0,00 0,00 0,15 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: KPMG

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Rhön-Klinikum
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
704230 DE0007042301 AG 924,08 Mio € 19.06.1991 Halten 9F2G86FM+GX
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
23,00 28,72 0,80 23,59 0,74 8,48 0,63
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
0,15 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
03.06.2025 08.05.2025 07.08.2025 07.11.2024 27.03.2025
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-0,72%
13,80 €
ATH 32,12 €
+7,45% +12,57% +38,00% +32,69% +452,00%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL